Top section
Top section
Ygar el Harrar moves from growth capital and solutions team
Capital raise and investor selldown follow €3bn raise by Engie on Friday evening
It's easy for investment bankers to get jaded about awards ceremonies, but they are missing the point
More articles
More articles
More articles
-
Chinese biotechnology company Brii Biosciences has raised HK$2.48bn ($319.7m) from its Hong Kong IPO, after pricing the deal at the top of the marketed range. -
Philippines-based real estate developer Filinvest Land has won IPO approval for a real estate investment trust (Reit), as the asset class grows in popularity in the country.
-
China's latest crackdown of three of its technology companies has a clear message for firms looking to list in the US — and investors wanting to buy their shares.
-
Rothschild & Co has hired Timothy Lufkin as a managing director covering financial sponsors within its global advisory business in New York. Lufkin previously worked at Truist and its predecessor, BB&T Capital Markets.
-
UK private equity group Bridgepoint has confirmed its intention to float on the London Stock Exchange.
-
Hong Kong’s stock exchange is planning to launch a new platform to cut the IPO settlement process, often criticised for being longer than on other global bourses.
Sub-sections
shared comment list
